Cetuximab & Panitumumab
Erbitux · Vectibix · Anti-EGFR antibody
TRPM6 magnesium wasting.
LYTE
MildOpen →
Antitumor antibiotic
Dactinomycin (actinomycin D)
Cosmegen · DACT
Actinomycin antibiotic whose renal risk is indirect: tumor lysis in chemosensitive pediatric tumors, with hepatic veno-occlusive disease as the signature organ toxicity.
Moderateearly-cytotoxic · approved 1964
Wilms tumorRhabdomyosarcoma and other soft-tissue sarcomasEwing sarcomaGestational trophoblastic neoplasiaTesticular germ-cell tumors (regimen component)
Signature kidney injury
Electrolyte Wasting
Direct nephrotoxicity is not an established feature of dactinomycin. The clinically relevant renal risk is tumor lysis syndrome (TLS) when used against bulky, chemosensitive pediatric tumors; precise incidence attributable to dactinomycin alone is not quantified, as it is given in multi-agent regimens.
Source: Carmichael et al., case report 2013 (TLS); not quantified as a single agent
Mechanism of kidney injury
No characteristic direct tubular or glomerular toxin. Renal involvement is secondary: rapid lysis of treatment-sensitive tumor cells releases uric acid, potassium and phosphate, producing uric-acid and calcium-phosphate intratubular precipitation and AKI; volume depletion from chemotherapy-associated nausea/vomiting can add a prerenal component. The classic dactinomycin organ toxicity is hepatic sinusoidal obstruction syndrome (veno-occlusive disease), not nephrotoxicity.
Clinical presentation
When TLS occurs, hyperuricemia, hyperkalemia, hyperphosphatemia, hypocalcemia and rising creatinine within days of starting therapy in a child with a large tumor burden. Hepatic VOD presents separately with painful hepatomegaly, weight gain, ascites and thrombocytopenia and can secondarily threaten renal perfusion.
Onset
TLS within hours to days of initiating effective chemotherapy; VOD typically within the first weeks of treatment.
Reversibility
Reversible
Anticancer mechanism
Chromopeptide antitumor antibiotic that intercalates into double-stranded DNA at GC-rich sequences, blocking RNA polymerase-dependent transcription and, at higher concentrations, DNA synthesis, leading to apoptosis.
Management
Manage TLS with hydration, uric-acid lowering (allopurinol/rasburicase), correction of electrolytes, and renal replacement therapy if refractory. VOD is managed supportively with attention to preserving renal and respiratory function; consider defibrotide in severe hepatic VOD. There is no dactinomycin-specific tubular antidote.
Risk factors
- Bulky or rapidly proliferating chemosensitive tumor (e.g., advanced Wilms tumor)
- Pre-existing volume depletion or reduced kidney function
- Young age and right-sided/large unilateral renal tumors (VOD risk)
- Inadequate hydration or uric-acid prophylaxis
Prevention
- Risk-stratify for TLS before cytoreductive therapy
- Aggressive IV hydration
- Allopurinol or rasburicase per TLS risk
- Monitor liver function and weight for early VOD recognition
- Avoid concurrent volume depletion
Note · The single-kidney state common in Wilms tumor survivors (post-nephrectomy) heightens the importance of nephron preservation, making any superimposed insult clinically significant.
Clinical depth
Renal dose adjustment
No well-established renal dose-adjustment scheme; dactinomycin is largely excreted in bile/feces with minor renal elimination. Dose modification is generally driven by hepatic toxicity and myelosuppression rather than kidney function.
Dialyzability & ESKD dosing
Not meaningfully dialyzable; high tissue binding and predominantly biliary/fecal elimination. Dialysis has a role only for managing TLS-related metabolic derangements, not for drug removal.
Differential diagnosis
Distinguish TLS-related AKI from prerenal AKI due to vomiting/poor intake, from obstructive uropathy by tumor mass, and from VOD-associated hepatorenal physiology. Direct dactinomycin tubular toxicity is a diagnosis of exclusion and is not well supported.
Monitoring
- Serum creatinine and electrolytes (K, phosphate, calcium, uric acid) during cytoreduction
- Liver function tests, weight and abdominal exam for VOD
- Urine output
- CBC
Key trials & series
- NWTS/COG and SIOP Wilms tumor protocols establishing vincristine/dactinomycin-based regimens (regimen-level evidence; renal events reported as TLS and VOD in associated literature)
Clinical pearls
- Think electrolytes and tumor lysis, not direct tubular toxicity, when a child on dactinomycin develops AKI.
- Hepatic veno-occlusive disease is the signature dactinomycin organ toxicity and can secondarily compromise the kidney through volume shifts.
- Many Wilms tumor patients have a solitary kidney after nephrectomy, so protect remaining nephron mass.
Where it strikes
Nephron segments
Tubular Lumen
The urine flow path
Vasculature / Endothelium
Glomerular & peritubular capillaries
Injury signatures
Electrolyte WastingPrerenal / Hemodynamic AKI
Beyond the kidney
Class-level context for the major non-renal toxicities of antitumor antibiotics.
Pulmonary
Pneumonitis, ILD, effusions, hypertension
- Mitomycin / bleomycin pulmonary toxicity
Hematologic
Cytopenias, thrombosis, TMA
- Cumulative myelosuppression
Evidence
4 peer-reviewed references. Citation metadata via PubMed / NLM.
PMIDHepatic veno-occlusive disease in Wilms' tumor.Kullendorff CM et al. · Eur J Pediatr Surg 1996 · PMID 9007466Prospective pediatric series documenting actinomycin-D-associated hepatic veno-occlusive disease in Wilms tumor and emphasizing preservation of renal function during supportive care.PMIDDelayed tumor resection in a 5-year-old child with bilateral Wilms tumor.Carmichael SP et al. · J Surg Case Rep 2013 · PMID 24964423Case of tumor lysis syndrome (elevated uric acid) complicating vincristine/dactinomycin/doxorubicin neoadjuvant chemotherapy for Wilms tumor, managed with hyperhydration and alkalinization.LandmarkThe tumor lysis syndrome.Howard SC et al. · N Engl J Med 2011 · PMID 21561350Authoritative review of tumor lysis syndrome pathophysiology, risk stratification and prevention relevant to chemosensitive pediatric tumors treated with dactinomycin-containing regimens.LandmarkAcute Kidney Injury in Patients with Cancer.Rosner MH et al. · N Engl J Med 2017 · PMID 28467867Onconephrology review framing tumor lysis and prerenal mechanisms of AKI in cancer patients.